[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma

Anthony G. McCluskey; Marie Boyd; Mark N. Gaze; Robert J. Mairs

doi:10.1016/j.canlet.2004.11.062

[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma

Anthony G. McCluskey^*
, Marie Boyd
, Mark N. Gaze
, Robert J. Mairs

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

MIBG is selectively concentrated in neuroblastoma cells, and radioiodinated MIBG has been used with some success for targeted radiotherapy. However, long-term cure remains elusive, and the topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy.
While synergistic killing by combinations of ionising radiation and topoisomerase I inhibitors has been reported, there is no consensus on optimal scheduling. Furthermore, there has been no attempt to demonstrate radiopotentiation by topoisomerase I inhibitors and targeted radiotherapy. We are investigating various scheduled combinations of topotecan and [131I]MIBG on neuroblastoma cells, and preliminary data suggests that topotecan induces increased accumulation of [131I]MIBG in vitro.

Original language	English
Pages (from-to)	221-227
Number of pages	7
Journal	Cancer Letters
Volume	228
Issue number	1-2
Early online date	1 Jun 2005
DOIs	https://doi.org/10.1016/j.canlet.2004.11.062
Publication status	Published - 18 Oct 2005

Keywords

[131I]MIBG
topotecan
targeted radiotherapy

Access to Document

10.1016/j.canlet.2004.11.062

Global clinical translation of a novel combination therapy for neuroblastoma using 131I MIBG nand topotecan- Matin trial
Boyd, M. (Participant)
Impact: Health and welfare - new products, guidelines and services

Cite this

@article{ca0e488a2eb6414c84f8ae17a6e729d9,

title = "[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma",

abstract = "MIBG is selectively concentrated in neuroblastoma cells, and radioiodinated MIBG has been used with some success for targeted radiotherapy. However, long-term cure remains elusive, and the topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. While synergistic killing by combinations of ionising radiation and topoisomerase I inhibitors has been reported, there is no consensus on optimal scheduling. Furthermore, there has been no attempt to demonstrate radiopotentiation by topoisomerase I inhibitors and targeted radiotherapy. We are investigating various scheduled combinations of topotecan and [131I]MIBG on neuroblastoma cells, and preliminary data suggests that topotecan induces increased accumulation of [131I]MIBG in vitro.",

keywords = "[131I]MIBG, topotecan, targeted radiotherapy",

author = "McCluskey, \{Anthony G.\} and Marie Boyd and Gaze, \{Mark N.\} and Mairs, \{Robert J.\}",

year = "2005",

month = oct,

day = "18",

doi = "10.1016/j.canlet.2004.11.062",

language = "English",

volume = "228",

pages = "221--227",

number = "1-2",

}

TY - JOUR

T1 - [131I]MIBG and topotecan

T2 - a rationale for combination therapy for neuroblastoma

AU - McCluskey, Anthony G.

AU - Boyd, Marie

AU - Gaze, Mark N.

AU - Mairs, Robert J.

PY - 2005/10/18

Y1 - 2005/10/18

N2 - MIBG is selectively concentrated in neuroblastoma cells, and radioiodinated MIBG has been used with some success for targeted radiotherapy. However, long-term cure remains elusive, and the topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. While synergistic killing by combinations of ionising radiation and topoisomerase I inhibitors has been reported, there is no consensus on optimal scheduling. Furthermore, there has been no attempt to demonstrate radiopotentiation by topoisomerase I inhibitors and targeted radiotherapy. We are investigating various scheduled combinations of topotecan and [131I]MIBG on neuroblastoma cells, and preliminary data suggests that topotecan induces increased accumulation of [131I]MIBG in vitro.

AB - MIBG is selectively concentrated in neuroblastoma cells, and radioiodinated MIBG has been used with some success for targeted radiotherapy. However, long-term cure remains elusive, and the topoisomerase I inhibitor topotecan may improve upon existing [131I]MIBG therapy. While synergistic killing by combinations of ionising radiation and topoisomerase I inhibitors has been reported, there is no consensus on optimal scheduling. Furthermore, there has been no attempt to demonstrate radiopotentiation by topoisomerase I inhibitors and targeted radiotherapy. We are investigating various scheduled combinations of topotecan and [131I]MIBG on neuroblastoma cells, and preliminary data suggests that topotecan induces increased accumulation of [131I]MIBG in vitro.

KW - [131I]MIBG

KW - topotecan

KW - targeted radiotherapy

U2 - 10.1016/j.canlet.2004.11.062

DO - 10.1016/j.canlet.2004.11.062

M3 - Article

SN - 0304-3835

VL - 228

SP - 221

EP - 227

JO - Cancer Letters

JF - Cancer Letters

IS - 1-2

ER -

[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma

Abstract

Keywords

Access to Document

Fingerprint

Impacts

Global clinical translation of a novel combination therapy for neuroblastoma using 131I MIBG nand topotecan- Matin trial

Cite this